Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Rodolfo F Perini"'
Autor:
Dhananjay D. Marathe, Petra M. Jauslin, Huub Jan Kleijn, Carolina deMiranda Silva, Anne Chain, Thomas Bateman, Peter M. Shaw, Anson K. Abraham, Eunkyung A. Kauh, Yanfang Liu, Rodolfo F. Perini, Dinesh P. deAlwis, Lokesh Jain
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1499-1510 (2023)
Abstract Belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA) is an oral, potent inhibitor of hypoxia‐inducible factor 2α, approved for the treatment of certain patients with von Hippel–Lindau (VHL) disease‐associated renal cell carcinoma
Externí odkaz:
https://doaj.org/article/9fb57ee9c9224d38a940c36af9575776
Autor:
Neil J. Shah, Sneha D. Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Nicholas J. Robert, Nicholas J. Vogelzang, Rodolfo F. Perini, Robert J. Motzer
Publikováno v:
European Urology Open Science, Vol 49, Iss , Pp 110-118 (2023)
Background: Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on real-world usage and outcomes are limited. Objective: To examine real-world t
Externí odkaz:
https://doaj.org/article/a10202e74530417c9bf14f1c997b9f5b
Autor:
Antoni Ribas, Toni K. Choueiri, Rodolfo F. Perini, Blanca Homet Moreno, Xinxin Shu, Seth Robey, Lokesh Jain, Marihella James, Shailender Bhatia, Deborah J. Wong, Nancy A. Dawson, Donald P. Lawrence, Wen-Jen Hwu, David F. McDermott, John A. Thompson, F. Stephen Hodi, Michael B. Atkins
Purpose: Pembrolizumab monotherapy, ipilimumab monotherapy, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a51e52add57777cc2d463d414a0e017
https://doi.org/10.1158/1078-0432.c.6527397.v1
https://doi.org/10.1158/1078-0432.c.6527397.v1
Autor:
Antoni Ribas, Toni K. Choueiri, Rodolfo F. Perini, Blanca Homet Moreno, Xinxin Shu, Seth Robey, Lokesh Jain, Marihella James, Shailender Bhatia, Deborah J. Wong, Nancy A. Dawson, Donald P. Lawrence, Wen-Jen Hwu, David F. McDermott, John A. Thompson, F. Stephen Hodi, Michael B. Atkins
Treatment-Related Adverse Events Occurring in {greater than or equal to}1 Patient Treated With Pembrolizumab plus Ipilimumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5a64cf4ee8ebdd137cf92b274d8b1f
https://doi.org/10.1158/1078-0432.22469943
https://doi.org/10.1158/1078-0432.22469943
Autor:
Robert Motzer, Saby George, Jaime R Merchan, Thomas E Hutson, Xun Song, Rodolfo F Perini, Ran Xie, Urmi Bapat, Javier Puente
Publikováno v:
The Oncologist.
BackgroundLenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used CLEAR data to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60c9e3f831dcae11a85027550854f15e
https://doi.org/10.1093/oncolo/oyac269
https://doi.org/10.1093/oncolo/oyac269
Autor:
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Naveen S Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas Hutson, Carlos Alemany, Bradley McGregor, Thomas Powles, Viktor Grünwald, Boris Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C Goh, Michael Staehler, Jaime R Merchan, Ran Xie, Rodolfo F Perini, Kalgi Mody, Jodi McKenzie, Camillo G Porta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c2da15b8e2e8a92751b8777549e5fec
https://www.ncbi.nlm.nih.gov/pubmed/36858721
https://www.ncbi.nlm.nih.gov/pubmed/36858721
Autor:
Jasmine Lin, William G. Kaelin, Katherine A. Janeway, Ari J. Wassner, Brent R. Weil, Sara O. Vargas, Steven G. DuBois, Jill A. Madden, Junne Kamihara, Kayla V. Hamilton, Stephan D. Voss, Rodolfo F. Perini, Matthew M. Heeney, Naseem J. Zojwalla, Alma Imamovic, Jessica A. Pollard, Catherine B. Wall, Catherine Clinton
Publikováno v:
New England Journal of Medicine. 385:2059-2065
The integration of genomic testing into clinical care enables the use of individualized approaches to the management of rare diseases. We describe the use of belzutifan, a potent and selective small-molecule inhibitor of the protein hypoxia-inducible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76b51b57488fad7b1852b2bc20689862
https://doi.org/10.1056/nejmoa2110051
https://doi.org/10.1056/nejmoa2110051
Autor:
Othon Iliopoulos, Rodolfo F. Perini, Vivek Narayan, Jodi K. Maranchie, Sarah J. Welsh, Frede Donskov, Eric Jonasch, Stéphane Oudard, Sanjay Thamake, Benjamin L. Maughan, Mk Investigators, Eric Kristopher Park, Tobias Else, W. Kimryn Rathmell, Ramaprasad Srinivasan, W. Marston Linehan
Publikováno v:
Jonasch, E, Donskov, F, Iliopoulos, O, Rathmell, W K, Narayan, V K, Maughan, B L, Oudard, S, Else, T, Maranchie, J K, Welsh, S J, Thamake, S, Park, E K, Perini, R F, Linehan, W M, Srinivasan, R & the MK-6482-004 Investigators 2021, ' Belzutifan for renal cell carcinoma in von Hippel-Lindau disease ', New England Journal of Medicine, vol. 385, no. 22, pp. 2036-2046 . https://doi.org/10.1056/NEJMoa2103425
N Engl J Med
N Engl J Med
BACKGROUND: Patients with von Hippel–Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS: In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1438610bde404348fe5c3a5618e91497
https://doi.org/10.1056/nejmoa2103425
https://doi.org/10.1056/nejmoa2103425
Autor:
Tobias Arkenau, Mark Voskoboynik, David F. McDermott, Robert E. Hawkins, Simon Chowdhury, Martin H. Voss, Isabelle Naeije, Albert Reising, Rodolfo F. Perini, J. R. Infante, Paola Aimone
Publikováno v:
Clin Genitourin Cancer
Background This study assessed whether antiangiogenic treatment may potentiate immune checkpoint blockade in patients with advanced renal cell carcinoma. Patients and Methods This was an open-label, two-part, multicenter study involving treatment-nai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::830ba25e9cfe3c553e383223d321ae28
https://doi.org/10.1016/j.clgc.2021.04.007
https://doi.org/10.1016/j.clgc.2021.04.007
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560f50f96435950099b910b1a10224ee
https://doi.org/10.1016/s1470-2045(21)00241-2
https://doi.org/10.1016/s1470-2045(21)00241-2